Ask for high quality link by putting your email below

The extracellular matrix (ECM) is present in all solid tissues and is a master regulator of cell behavior and phenotype. The ECM in each tissue is characterized by its biochemical and biophysical properties, which are modified in many different types of disease, especially cancer. Hyaluronic acid (HA), as a biopolymer, has emerged as a remarkable ECM component by its viscoelastic properties, its hygroscopic capacities and the diversity of cell processes it controls in health and disease.

BIOMIMESYS®, a patented HA-based hydroscaffold, is a highly reproducible and physiological matrix that is suitable for long-term 3D cell culture. Using BIOMIMESYS® Oncology – made of HA biofunctionalized with undenaturated collagen I – we investigated the influence of (i) matrix composition (with/without laminin) and (ii) stiffness on the growth and expression of CD44 (a receptor of HA) in spheroids made of breast cancer cell lines (MCF7, MDA-MB-231) and normal cells (MCF10A) along time. Analyses were carried out using high content analysis/screening (HCA/HCS, high throughput confocal microscopy).

As a whole, the results showed that the cell growth was lowered in the presence of laminin but promoted with increased stiffness. Except for MCF10A cells, the expression of CD44 had the tendency to increase over time, while the stiffness and the presence of laminin had no significant impact on its expression. Given that BIOMIMESYS® is a highly defined and easily tunable matrix, this physiological 3D cell culture system allows to study the impact of biochemical and biophysical properties of the matrix.

By better mimicking the cancer microenvironment – including the ECM – the new generation of 3D cell culture systems might help to discover new effective anti-cancer therapies. In this frame, our aim is to study the response of cancer cells in BIOMIMESYS® to a large set of anti-tumor molecules, using our HCS platform.

Categories: Posters

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

1 Comment

Back from SFBMEC congress 2019 | HCS Pharma · July 25, 2019 at 9:41 am

[…] poster and discuss about BIOMIMESYS® hydroscaffold in cancer research! You can still download it here. Special thanks to the scientific committe and Com&Co company for organizing the meeting, which […]

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.